Match each clinical scenario describing a targeted immunomodulatory therapy to its direct foundational immunopathologic consequence or the mechanism of its signature adverse effect.
- A 52-year-old female receiving targeted therapy that prevents the CD28 receptor on T cells from being outcompeted for its ligands.Disruption of peripheral tolerance due to continuous costimulatory signaling, manifesting as destructive hypophysitis.
- A 34-year-old male with relapsing-remitting demyelinating disease treated with an agent that blocks the interaction between VLA-4 and VCAM-1.Failure of lymphocytes to firmly adhere to central nervous system endothelium, allowing opportunistic polyomavirus reactivation.
- A 45-year-old female with severe, corticosteroid-dependent asthma treated with a biologic that neutralizes a major Th2-derived differentiation factor.Depletion of a terminal effector cell population responsible for major basic protein release and helminth cytotoxicity.
- A 28-year-old male with episodic hemoglobinuria and venous thrombosis prescribed a monoclonal antibody that inhibits the terminal complement cascade.Inability to form the cytolytic membrane pore, resulting in extreme vulnerability to encapsulated, gram-negative diplococci.
- A 61-year-old female with severe erosive polyarthritis treated with a recombinant fusion protein consisting of a receptor extracellular domain linked to human IgG1 Fc.Loss of synergistic cytokine signaling required for the maintenance of epithelioid macrophages in caseating granulomas.
Answer
The correct pairings link specific immunomodulatory mechanisms to their downstream cellular consequences: CTLA-4 inhibition with disrupted peripheral tolerance, VLA-4 blockade with impaired CNS transmigration, IL-5 neutralization with eosinophil depletion, terminal complement inhibition with MAC failure, and TNF-alpha decoy receptors with granuloma breakdown.
Each therapy targets a distinct immunologic pathway. Anti-CTLA-4 prevents the inhibitory signal in the immunological synapse, causing autoimmunity. VLA-4 blockade stops integrin-mediated firm adhesion, preventing CNS immunosurveillance. Anti-IL-5 removes the survival signal for eosinophils. C5 inhibition stops the membrane attack complex. TNF-alpha decoy receptors remove the macrophage-activating signal necessary for granuloma integrity.
Step-by-Step Solution
Key Concept
The immunopathologic consequences of targeted biologic therapies are directly related to the specific cellular interactions, receptor bindings, and cytokine pathways they inhibit.